NDA 17313, held by Pharmalucence. Iodohippurate Sodium I-131.
As of Nov 15, 2026, NDA 17313 (Iodohippurate Sodium I 131), held by Pharmalucence, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Iodohippurate Sodium I 1310.2mCi/ML ยท injectable;injection | Iodohippurate Sodium I-131 | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
